Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 13, Issue 9, Pages 1149-1157Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.13.9.1149
Keywords
drug discovery; privileged structure; silicon
Categories
Ask authors/readers for more resources
There remains considerable pressure on the pharmaceutical industry to increase productivity and reduce the attrition of drug candidates. Genomics, parallel chemistry and high-throughput biology have not yielded the anticipated benefits, resulting in a renewed focus on validated targets and an aim to generate drugs directed towards such targets, which have a clear advantage. One strategy to identify and develop best-in-class drugs is to apply a high degree of innovation in chemistry and apply this to targets from gene families that have been clinically validated as tractable and drugable. The application of organosilicon medicinal chemistry in the context of privileged structures to aid drug design and development is one such innovative approach that is reviewed in this paper.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available